Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06766461 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis

Study acronym: BULLSEYE
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.
Trial Details
NCT Number NCT06766461
Lead Sponsor Erasmus Medical Center
Collaborators: Maasstad Hospital, Albert Schweitzer Hospital
Conditions Sepsis - to Reduce Mortality in the Intensive Care Unit, Sepsis, Septic Shock
Enrollment 980 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov